Nebenwirkungen · Kisqali
Kisqali 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 16
HOS-136290 · Präparat HOS-097860
QT prolongation In the phase III study in patients with early breast cancer, 5.3% of patients in the Kisqali plus AI arm and 1.4% of patients in the AI alone arm reported events of QT interval prolongation. In the Kisqali plus AI arm QT interval prolongation events were presented primarily by ECG QT prolonged (4.3%) which was the only confirmed adverse reaction with Kisqali. Dose interruptions due to ECG QT prolonged and syncope were reported in 1.1% of patients treated with Kisqali. Dose adjustments due to ECG QT prolonged were reported in 0.1% of patients treated with Kisqali.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:22:00Z · SHA-256 808e9743b462916472557a0fc0a032e5a4cdf4c2e48d8fd0f992823e92cc05c1 · Passage 74c671ee40cde5d056d30b91653a4ca99f65a497f1267d82e0da1a0098c719cd · Zeichen 13985–14570 im Abschnitt